Luma Group closes $410 million, 15-year life-science venture fund
Luma Group announced that its first life‑science venture capital fund has reached final close, raising $410 million for a 15‑year investment period. The New York‑based firm said the capital will be used to back emerging biotech companies through key development stages.
The fund, named LumaBio Fund I, already includes stakes in more than ten companies, among them eye‑disease specialist Character Biosciences, rebranded Belgian firm Coultreon Biopharma, and cellular‑rejuvenation startup Altos Labs. Early success was highlighted by the acquisition of a co‑created company, Vaccine Company, by Eli Lilly for up to $1.55 billion.
Luma’s founder Joshua Fink emphasized the firm’s belief that patient, long‑term capital can translate breakthrough science into therapies that improve millions of lives. The fund’s structure is designed to support portfolio companies from discovery through commercialization.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Luma locks down 15-year, $410M fund for life science investments”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that